Muhammad Zaki Hidayatullah Fadlullah

Also affiliated with Huntsman Cancer Institute, University of Manchester, Cancer Research UK Manchester Institute

Biochemistry, Genetics and Molecular BiologyMedicineImmunology and Microbiology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 9 papers. Top paper: “Pembrolizumab and cabozantinib in recurrent metastatic head and neck squamous cell carcinoma: a phase 2 trial”.

Pembrolizumab and cabozantinib in recurrent metastatic head and neck squamous cell carcinoma: a phase 2 trial

Nature Medicine(2023)10.1038/s41591-023-02275-x

N/A

1.7DataRank · unranked

77 citations

Conor Steuer, Asari Ekpenyong, Ashley A. McCook‐Veal, Kelly R. Magliocca, Mihir R. Patel +18 more

Deciphering the Tumor–Immune–Microbe Interactions in HPV-Negative Head and Neck Cancer

Genes(2023)10.3390/genes14081599

N/A

0DataRank · unranked

5 citations

Samuel S. Coleman, Muhammad Zaki Hidayatullah Fadlullah, Daniel Spakowicz, Christine H. Chung, Aik Choon Tan +1 more

Response to high dose ipilimumab plus temozolomide after progression on standard or low dose ipilimumab in advanced melanoma: a retrospective analysis

Research Square(2023)10.21203/rs.3.rs-2997157/v1

N/A

0DataRank · unranked

1 citations

Muhammad Zaki Hidayatullah Fadlullah, Magdalena Kovacsovics-Bankowski, Berit Gibson, Umang Swami, Alyssa Erickson‐Wayman +14 more

Phase II trial of pembrolizumab, ipilimumab, and aspirin in melanoma: clinical outcomes and translational predictors of response

BJC Reports(2024)10.1038/s44276-024-00057-7

N/A

0DataRank · unranked

19 citations

Saya Jacob, Muhammad Zaki Hidayatullah Fadlullah, Chaorong Wu, Clinton Wu, Laura A. Huppert +16 more

Exploring the Landscape of Immune Checkpoint Inhibitor-Induced Adverse Events Through Big Data Mining of Pan-Cancer Clinical Trials

The Oncologist(2024)10.1093/oncolo/oyae012

N/A

0DataRank · unranked

5 citations

Ching-Nung Lin, Samuel S. Coleman, Arabella Young, Abdul Rafeh Naqash, Siwen Hu‐Lieskovan +2 more

A microRNA-regulated transcriptional state defines intratumoral CD8+ T cells that respond to immunotherapy

Cell Reports(2025)10.1016/j.celrep.2025.115301

N/A

0DataRank · unranked

11 citations

Ben Battistone, Kaylyn M. Bauer, Allison M. Weis, Cindy Barba, Muhammad Zaki Hidayatullah Fadlullah +19 more

Dramatic Responses to High-Dose Ipilimumab Plus Temozolomide After Progression on Standard- or Low-Dose Ipilimumab in Advanced Melanoma

Current Oncology(2025)10.3390/curroncol32030144

N/A

0DataRank · unranked

2 citations

Muhammad Zaki Hidayatullah Fadlullah, Magdalena Kovacsovics-Bankowski, Berit Gibson, Umang Swami, Alyssa Erickson‐Wayman +14 more

Plasma cell-free DNA methylation-based prognosis in metastatic castrate-resistant prostate cancer

npj Precision Oncology(2025)10.1038/s41698-025-01232-w

N/A

0DataRank · unranked

1 citations

Yijun Tian, Manishkumar S. Patel, Kapil Avasthi, Claire Hanson, Matt Larsen +11 more

Synovial sarcoma reprograms transcription by GBAF activation of polycomb targets and loss of CBAF enhancers

Nature Communications(2025)10.1038/s41467-025-67841-y

N/A

0DataRank · unranked

1 citations

Li Li, Kyllie Smith-Fry, Muhammad Zaki Hidayatullah Fadlullah, Lara Carroll, Linda Morrison +12 more